AstraZeneca (AZN) - Buy at 2725p

AstraZeneca (AZN) Investor activism is on the rise and one of the latest victims is the chief executive officer of AstraZeneca, David Brennan, who has decided to call it a day following disquiet over the company's performance, and investors calling for a management shake-up. The gap will be filled by the chief financial officer, Simon Lowth, who will be acting interim chief executive until a replacement is installed. The UK's second largest drug-maker by costs has been aggressively cutting costs, by reducing operations and cutting thousands of jobs, while maintaining cash flow to shareholders. Read the full story in the latest edition of Redmayne Bentley's Sharespotlight newsletter on Shareworld.